| scholarly article | Q13442814 |
| P356 | DOI | 10.1093/JNCI/87.7.506 |
| P698 | PubMed publication ID | 7707437 |
| P50 | author | Steve Charnock-Jone | Q57177791 |
| Andrew Marck Sharkey | Q41633924 | ||
| P2093 | author name string | K A Wright | |
| S K Smith | |||
| J McLaren | |||
| P J Barker | |||
| P R Twentyman | |||
| C A Boocock | |||
| P4510 | describes a project that uses | OV17R | Q54936883 |
| OV25R | Q54936887 | ||
| OV7 | Q54936905 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | endothelium | Q111140 |
| cell line | Q21014462 | ||
| P304 | page(s) | 506-516 | |
| P577 | publication date | 1995-04-01 | |
| P1433 | published in | Journal of the National Cancer Institute | Q400279 |
| P1476 | title | Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma | |
| P478 | volume | 87 |
| Q47743059 | A comparative study of the expression patterns for vegf, vegf-b/vrf and vegf-c in the developing and adult mouse |
| Q77733808 | A novel gene delivery system targeting cells expressing VEGF receptors |
| Q30429122 | Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial |
| Q75196511 | All three receptors for vascular endothelial growth factor (VEGF) are expressed on B-chronic lymphocytic leukemia (CLL) cells |
| Q38349912 | Angiogenesis and the expression of vascular endothelial growth factor in endometrium and placenta |
| Q36746626 | Angiogenesis in cancer |
| Q33919078 | Angiogenesis in epithelian ovarian cancer |
| Q73954429 | Angiogenesis in ovarian carcinoma: a formidable biomarker |
| Q73760972 | Angiogenesis in primary and metastatic epithelial ovarian carcinoma |
| Q34461788 | Angiogenesis inhibitors in the treatment of lung cancer |
| Q36431516 | Angiogenesis is associated with vascular endothelial growth factor expression in cervical intraepithelial neoplasia |
| Q33825273 | Angiogenesis of the ovary |
| Q53376658 | Angiogenetic protooncogene ets-1 induced neovascularization is involved in the metastatic process of testicular germ cell tumors. |
| Q37739569 | Anti-tumour activity of tivozanib, a pan-inhibitor of VEGF receptors, in therapy-resistant ovarian carcinoma cells |
| Q40677359 | Aplidine, a new anticancer agent of marine origin, inhibits vascular endothelial growth factor (VEGF) secretion and blocks VEGF-VEGFR-1 (flt-1) autocrine loop in human leukemia cells MOLT-4. |
| Q36134259 | Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma |
| Q74505899 | Association of vascular endothelial growth factor expression with tumor angiogenesis, survival and thymidine phosphorylase/platelet-derived endothelial cell growth factor expression in human colorectal cancer |
| Q37159495 | Bevacizumab for the treatment of advanced non-small-cell lung cancer |
| Q73112514 | Cell-retained isoforms of vascular endothelial growth factor (VEGF) are correlated with poor prognosis in osteosarcoma |
| Q33610969 | Chronic cocaine induces HIF-VEGF pathway activation along with angiogenesis in the brain |
| Q36089989 | Cisplatin plus paclitaxel and maintenance of bevacizumab on tumour progression, dissemination, and survival of ovarian carcinoma xenograft models |
| Q36623505 | Clinical implications of expression of vascular endothelial growth factor in metastatic lesions of ovarian cancers |
| Q73614411 | Clinical relevance of Flt1 and Tie1 angiogenesis receptors expression in B-cell chronic lymphocytic leukemia (CLL) |
| Q41372744 | Clinical significance of the determination of angiogenic factors |
| Q45798976 | Clinicopathological significance of hypoxia-inducible factor-1 alpha (HIF-1α) expression in gastric cancer |
| Q59799628 | Combination of triapine, olaparib, and cediranib suppresses progression of BRCA-wild type and PARP inhibitor-resistant epithelial ovarian cancer |
| Q34023344 | Combinatorial effect of non-steroidal anti-inflammatory drugs and NF-κB inhibitors in ovarian cancer therapy |
| Q61896370 | Comparative analysis of loss of heterozygosity and expression profi le in normal tissue, DCIS and invasive breast cancer |
| Q36292714 | Concentration of vascular endothelial growth factor (VEGF) in the serum of patients with suspected ovarian cancer |
| Q36622433 | Concentration of vascular endothelial growth factor in the tumour tissue as a prognostic factor of soft tissue sarcomas |
| Q48909870 | Contrast-enhanced ultrasonography for assessment of tumor vascularity in hepatocellular carcinoma |
| Q41778639 | Correlation of vascular endothelial growth factor expression with fibroblast growth factor-8 expression and clinico-pathologic parameters in human prostate cancer |
| Q38137570 | Current and future biologic markers for disease progression and relapse in testicular germ cell tumors: a review |
| Q41111895 | Cytokines in tumour growth, migration and metastasis |
| Q34129693 | DNA methylation regulates expression of VEGF-R2 (KDR) and VEGF-R3 (FLT4). |
| Q46122468 | Differential expression of VEGF ligands and receptors in prostate cancer |
| Q44251620 | Differential expression of VEGF receptors in adrenal atrophy induced by dexamethasone: a protective role of ACTH. |
| Q36293040 | Differential expression of vascular endothelial growth factor mRNA vs protein isoform expression in human breast cancer and relationship to eIF-4E. |
| Q38431573 | Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis Trial |
| Q78704136 | Distribution of vascular endothelial growth factor (VEGF) in prostate disease |
| Q35098085 | Diverse mechanisms for activation of Wnt signalling in the ovarian tumour microenvironment |
| Q34748791 | Double suicide genes driven by kinase domain insert containing receptor promoter selectively kill human lung cancer cells |
| Q39419250 | Down-modulation of TNFSF15 in ovarian cancer by VEGF and MCP-1 is a pre-requisite for tumor neovascularization |
| Q35922535 | ETS-1 protein regulates vascular endothelial growth factor-induced matrix metalloproteinase-9 and matrix metalloproteinase-13 expression in human ovarian carcinoma cell line SKOV-3. |
| Q40593958 | Effects of vascular endothelial growth factor expression on pathological characteristics and prognosis of osteosarcoma |
| Q35560094 | Effusion cytology in ovarian cancer: new molecular methods as aids to diagnosis and prognosis |
| Q44611371 | Endometriosis-associated ovarian carcinoma: differential expression of vascular endothelial growth factor and estrogen/progesterone receptors |
| Q48122829 | Enzymatic rationale and preclinical support for a potent protein kinase C beta inhibitor in cancer therapy |
| Q40612609 | Estrogen regulation of vascular endothelial growth factor gene expression in ZR-75 breast cancer cells through interaction of estrogen receptor alpha and SP proteins |
| Q36865053 | Evaluation of potentially predictive markers for anti-angiogenic therapy with sunitinib in recurrent ovarian cancer patients |
| Q79661656 | Evaluation of serum vascular endothelial growth factor (VEGF) and microvessel density (MVD) as prognostic indicators in carcinoma breast |
| Q36777298 | Evaluation of the angiogenesis inhibitor KR-31831 in SKOV-3 tumor-bearing mice using (64)Cu-DOTA-VEGF(121) and microPET. |
| Q37347027 | Evidence of a genetic link between endometriosis and ovarian cancer |
| Q43997195 | Expression and endocytosis of VEGF and its receptors in human colonic vascular endothelial cells |
| Q73668795 | Expression of angiogenesis factors in monolayer culture, multicellular spheroid and in vivo transplanted tumor by human ovarian cancer cell lines |
| Q34678882 | Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib |
| Q36671720 | Expression of the VEGF and angiopoietin genes in endometrial atypical hyperplasia and endometrial cancer. |
| Q78128696 | Expression of vascular endothelial growth factor (VEGF) and its receptors in human neuroblastoma |
| Q36431375 | Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels |
| Q73294135 | Expression of vascular endothelial growth factor and its receptors in the rhesus monkey (Macaca mulatta) endometrium and placenta during early pregnancy |
| Q53425142 | Expression of vascular endothelial growth factor in N-butyl-N-(4-hydroxybutyl)nitrosamine-induced rat bladder carcinogenesis. |
| Q50950759 | Expression of vascular endothelial growth factor in normal liver and hepatocellular carcinoma: an immunohistochemical study. |
| Q73289328 | Expression of vascular endothelial growth factor isoforms and platelet-derived endothelial cell growth factor in bladder cancer |
| Q42477154 | Expression of vascular endothelial growth factor receptors in human prostate cancer |
| Q53346120 | Expression of vascular endothelial growth factor related to 72-kilodalton metalloproteinase immunostaining in patients with serous ovarian tumors. |
| Q35746653 | Expresson of vascular endothelial growth factor, its receptors (FLT-1, KDR) and TSP-1 related to microvessel density and patient outcome in vertical growth phase melanomas |
| Q24608649 | GADD45 proteins: central players in tumorigenesis |
| Q36922247 | Gene therapy of gynaecological diseases |
| Q36464907 | Gene transfer approaches for gynecological diseases |
| Q35748149 | Generation of a syngeneic mouse model to study the effects of vascular endothelial growth factor in ovarian carcinoma. |
| Q41086267 | Hepatocyte growth factor stimulates motility, chemotaxis and mitogenesis in ovarian carcinoma cells expressing high levels of c-met |
| Q36608597 | High efficacy of CpG-ODN, cetuximab and cisplatin combination for very advanced ovarian xenograft tumors |
| Q35562421 | Identification of common mechanisms between endometriosis and ovarian cancer. |
| Q38710046 | Imaging-guided delivery of RNAi for anticancer treatment |
| Q34901858 | Immunization with synthetic VEGF peptides in ovarian cancer |
| Q30750084 | Immunolocalisation of the VEGF receptors FLT-1, KDR, and FLT-4 in diabetic retinopathy |
| Q42794629 | Importance of vascular phenotype by basic fibroblast growth factor, and influence of the angiogenic factors basic fibroblast growth factor/fibroblast growth factor receptor-1 and ephrin-A1/EphA2 on melanoma progression |
| Q40580539 | In vivo inhibition of tumor angiogenesis by a soluble VEGFR-2 fragment |
| Q43184381 | Incisor degeneration in rats induced by vascular endothelial growth factor/fibroblast growth factor receptor tyrosine kinase inhibition |
| Q44719653 | Induction of protein growth factor systems in the ovaries of transgenic mice overexpressing human type 2 lysophosphatidic acid G protein-coupled receptor (LPA2). |
| Q47273203 | Inhibition of both the autocrine and the paracrine growth of human leukemia with a fully human antibody directed against vascular endothelial growth factor receptor 2. |
| Q39880781 | Inhibition of cell proliferation, vascular endothelial growth factor and tumor growth by albendazole |
| Q31135653 | Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity |
| Q22254113 | Inhibition of vascular endothelial growth factor expression in HEC1A endometrial cancer cells through interactions of estrogen receptor alpha and Sp3 proteins |
| Q40211907 | Integrin regulation by vascular endothelial growth factor in human brain microvascular endothelial cells: role of alpha6beta1 integrin in angiogenesis |
| Q36824041 | Intramolecularly folded G-quadruplex and i-motif structures in the proximal promoter of the vascular endothelial growth factor gene |
| Q45862137 | Intraperitoneal gene therapy by rAAV provides long-term survival against epithelial ovarian cancer independently of survivin pathway |
| Q38152755 | Intravenous aflibercept in patients with platinum-resistant, advanced ovarian cancer: results of a randomized, double-blind, phase 2, parallel-arm study. |
| Q33897202 | Kinase inhibitors in cancer therapy: a look ahead |
| Q40416729 | LPA-induced epithelial ovarian cancer (EOC) in vitro invasion and migration are mediated by VEGF receptor-2 (VEGF-R2). |
| Q81101590 | Localization of the VEGF and angiopoietin genes in uterine carcinosarcoma |
| Q36722080 | Loss of ovarian function promotes angiogenesis in human ovarian carcinoma |
| Q38252667 | Macrophage colony-stimulating factor and cancer: a review |
| Q35903683 | Malignant effusions: from diagnosis to biology |
| Q46830786 | Micro-vessel density and the expression of vascular endothelial growth factor (VEGF) and platelet-derived endothelial cell growth factor (PdEGF) in classical Hodgkin lymphoma (HL). |
| Q35842085 | Molecular determinants of ovarian cancer plasticity |
| Q36904860 | Novel agents in ovarian cancer. |
| Q39692519 | Novel compounds with antiangiogenic and antiproliferative potency for growth control of testicular germ cell tumours |
| Q35085430 | Novel function for vascular endothelial growth factor receptor-1 on epidermal keratinocytes |
| Q37024446 | Novel soluble Flt-1 isoforms in plasma and cultured placental explants from normotensive pregnant and preeclamptic women. |
| Q28543021 | Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes |
| Q40412257 | Ovarian carcinoma cells and IL-1beta-activated human peritoneal mesothelial cells are possible sources of vascular endothelial growth factor in inflammatory and malignant peritoneal effusions |
| Q34781970 | Overexpression of Tumor Vascular Endothelial Growth Factor A May Portend an Increased Likelihood of Progression in a Phase II Trial of Bevacizumab and Erlotinib in Resistant Ovarian Cancer |
| Q34722935 | Pathological significance of vascular endothelial growth factor A isoform expression in human cancer |
| Q36791086 | Primary extraosseous Ewing sarcoma of the lung in children |
| Q36617666 | Production of VEGF and expression of the VEGF receptors Flt-1 and KDR in primary cultures of epithelial and stromal cells derived from breast tumours |
| Q36621710 | Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma |
| Q36077140 | Prognostic significance of vascular endothelial growth factor serum determination in women with ovarian cancer |
| Q36621924 | Prognostic value of vascular endothelial growth factor (VEGF) in head and neck squamous cell carcinomas |
| Q73670868 | Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients |
| Q53664103 | Prognostic value of vascular endothelial growth factor in Stage IB carcinoma of the uterine cervix. |
| Q39384319 | Promoter methylation status of VEGF receptor genes: a possible epigenetic biomarker to anticipate the efficacy of intracellular-acting VEGF-targeted drugs in cancer cells. |
| Q33770947 | Purinergic mechanisms in breast cancer support intravasation, extravasation and angiogenesis |
| Q73226531 | Quantification of VEGF mRNA expression in non-small cell lung cancer using a real-time quantitative reverse transcription-PCR assay and a comparison with quantitative competitive reverse transcription-PCR |
| Q28480617 | Quercetin-4'-O-β-D-glucopyranoside (QODG) inhibits angiogenesis by suppressing VEGFR2-mediated signaling in zebrafish and endothelial cells |
| Q40884078 | Release and complex formation of soluble VEGFR-1 from endothelial cells and biological fluids |
| Q36292232 | Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. |
| Q45873437 | Retroviral hybrid LTR vector strategy: functional analysis of LTR elements and generation of endothelial cell specificity |
| Q35829525 | Role of endothelin-1 in neovascularization of ovarian carcinoma |
| Q41060744 | Role of the hypoxia sensing system, acidity and reproductive hormones in the variability of vascular endothelial growth factor induction in human breast carcinoma cell lines |
| Q35753569 | Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization |
| Q33771212 | Role of vascular endothelial growth factor inhibitors in the treatment of gynecologic malignancies |
| Q39628302 | SR16388: a steroidal antiangiogenic agent with potent inhibitory effect on tumor growth in vivo |
| Q36394925 | Science and technology of the emerging nanomedicines in cancer therapy: A primer for physicians and pharmacists |
| Q38472672 | Serum vascular endothelial growth factor is a candidate biomarker of metastatic tumor response to ex vivo gene therapy of renal cell cancer |
| Q35954103 | Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer |
| Q34774019 | Soluble flt-1 and the angiopoietins in the development and regulation of placental vasculature |
| Q84491268 | Sorafenib as a third line therapy in patients with epithelial ovarian cancer or primary peritoneal cancer: a phase II study |
| Q24315888 | Src homology 2 (SH2) domain containing protein tyrosine phosphatase-1 (SHP-1) dephosphorylates VEGF Receptor-2 and attenuates endothelial DNA synthesis, but not migration |
| Q34878868 | Targeted therapies in epithelial ovarian cancer: Molecular mechanisms of action |
| Q39747275 | Targeting of VEGF-dependent transendothelial migration of cancer cells by bevacizumab. |
| Q24307613 | The VEGF-C/Flt-4 axis promotes invasion and metastasis of cancer cells |
| Q22010690 | The effects of angiogenic growth factors on extravillous trophoblast invasion and motility |
| Q36623444 | The expression of vascular endothelial growth factor C and its receptors in non-small cell lung cancer |
| Q33706710 | The rationale and future potential of angiogenesis inhibitors in neoplasia |
| Q37937859 | The role of targeted therapy in ovarian cancer |
| Q36627750 | The tumor microenvironment: key to early detection |
| Q35011885 | Therapies directed at vascular endothelial growth factor |
| Q64229289 | Thymoquinone, an Active Constituent of Black Seed Attenuates CCl4 Induced Liver Injury in Mice via Modulation of Antioxidant Enzymes, PTEN, P53 and VEGF Protein |
| Q64997568 | Tubeimoside-1 inhibits the proliferation and metastasis by promoting miR-126-5p expression in non-small cell lung cancer cells. |
| Q37308766 | Tumor cell expression of vascular endothelial growth factor receptor 2 is an adverse prognostic factor in patients with squamous cell carcinoma of the lung |
| Q30359568 | Ultrasound Molecular Imaging of Angiogenesis Using Vascular Endothelial Growth Factor-Conjugated Microbubbles. |
| Q35093616 | VEGF blocking therapy in the treatment of cancer |
| Q38293320 | VEGF expression and enhanced production by gonadotropins in ovarian epithelial tumors |
| Q81326073 | VEGF receptor inhibition slows the progression of polycystic kidney disease |
| Q81019483 | VEGF significance in peritoneal recurrence from gastric cancer |
| Q80531924 | VEGF, VEGFRs expressions and activated STATs in ovarian epithelial carcinoma |
| Q36677407 | VEGF/VEGFR signalling as a target for inhibiting angiogenesis |
| Q39797640 | VEGFR-2 silencing by small interference RNA (siRNA) suppresses LPA-induced epithelial ovarian cancer (EOC) invasion |
| Q36621786 | Vascular endothelial growth factor (VEGF) expression is a prognostic factor for radiotherapy outcome in advanced carcinoma of the cervix |
| Q40706795 | Vascular endothelial growth factor (VEGF) is expressed by neoplastic Hodgkin-Reed-Sternberg cells in Hodgkin's disease |
| Q36292182 | Vascular endothelial growth factor (VEGF) mRNA isoform expression pattern is correlated with liver metastasis and poor prognosis in colon cancer |
| Q80565368 | Vascular endothelial growth factor C and vascular endothelial growth factor receptor 2 are related closely to the prognosis of patients with ovarian carcinoma |
| Q73179856 | Vascular endothelial growth factor and its correlation with angiogenesis and p53 expression in prostate cancer |
| Q73585854 | Vascular endothelial growth factor and its receptors in normal human testicular tissue |
| Q52129432 | Vascular endothelial growth factor and vascular endothelial growth factor receptor-2 expression in the chick embryo area vasculosa. |
| Q37059490 | Vascular endothelial growth factor expression and inhibition in uveal melanoma cell lines |
| Q36414088 | Vascular endothelial growth factor expression correlates with serum CA125 and represents a useful tool in prediction of refractoriness to platinum-based chemotherapy and ascites formation in epithelial ovarian cancer |
| Q53359012 | Vascular endothelial growth factor expression in early stage ovarian carcinoma |
| Q42047538 | Vascular endothelial growth factor expression in ovarian serous carcinomas and its effect on tumor proliferation |
| Q38445978 | Vascular endothelial growth factor expression in serous ovarian carcinoma: relationship with topoisomerase II alpha and prognosis |
| Q36621192 | Vascular endothelial growth factor expression is independent of hypoxia in human malignant glioma spheroids and tumours |
| Q79085959 | Vascular endothelial growth factor in adnexal masses |
| Q35678769 | Vascular endothelial growth factor in females of reproductive age. |
| Q34107669 | Vascular endothelial growth factor in ovarian cancer |
| Q53328978 | Vascular endothelial growth factor in ovarian cyst fluid. |
| Q37357790 | Vascular endothelial growth factor is produced by peritoneal fluid macrophages in endometriosis and is regulated by ovarian steroids. |
| Q73047951 | Vascular endothelial growth factor measured in platelet poor plasma allows optimal separation between cancer patients and volunteers: a key to study an angiogenic marker in vivo? |
| Q28469224 | Vascular endothelial growth factor mediates intracrine survival in human breast carcinoma cells through internally expressed VEGFR1/FLT1 |
| Q57005503 | Vascular endothelial growth factor messenger ribonucleic acid expression in human ovarian and endometrial cancer |
| Q40688027 | Vascular endothelial growth factor modulates the transendothelial migration of MDA-MB-231 breast cancer cells through regulation of brain microvascular endothelial cell permeability |
| Q34166351 | Vascular endothelial growth factor receptor-1 activation mediates epithelial to mesenchymal transition in hepatocellular carcinoma cells |
| Q24305184 | Vascular endothelial growth factor receptor-1 promotes migration and invasion in pancreatic carcinoma cell lines |
| Q28345678 | Vascular endothelial growth factor receptor-2-mediated mitogenesis is negatively regulated by vascular endothelial growth factor receptor-1 in tumor epithelial cells |
| Q35747351 | Vascular endothelial growth factor-165 overexpression stimulates angiogenesis and induces cyst formation and macrophage infiltration in human ovarian cancer xenografts |
| Q39664069 | Vascular endothelial growth factor-C promotes the growth and invasion of gallbladder cancer via an autocrine mechanism |
| Q41078547 | Vascular endothelial growth factor: environmental controls and effects in angiogenesis. |
| Q41221212 | Vascular growth factors and receptors in capillary hemangioblastomas and hemangiopericytomas |
| Q41510549 | Visualization of tumor angiogenesis using MR imaging contrast agent Gd-DTPA-anti-VEGF receptor 2 antibody conjugate in a mouse tumor model |
| Q35753158 | What is the role of vascular endothelial growth factor-related molecules in tumor angiogenesis? |
| Q40967208 | Wide spectrum of antitumor activity of a neutralizing monoclonal antibody to human vascular endothelial growth factor |
Search more.